Symbiosis Group

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Biosplice Therapeutics is a company focused on medical research and development in tissue-level regeneration. Its platform, which originated from small molecule-based modulation of the Wnt signaling pathway, is designed to create therapeutics for a variety of degenerative diseases, including osteoarthritis and certain cancers. By discovering new biological targets and processes, Biosplice Therapeutics aims to develop innovative small molecule drugs that could provide curative therapies for multiple conditions. The company's objective is to enhance patient health through a comprehensive technology platform dedicated to modulating regenerative pathways.

Finch Therapeutics develops microbial therapies to treat serious medical conditions driven by microbiome disruption. It uses machine learning algorithms to identify microbes from successful clinical datasets, enabling early retirement of translational risk.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.